|
US585592A
(en)
|
|
1897-06-29 |
|
Reversing-valve |
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
US7087411B2
(en)
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
|
US20070258987A1
(en)
|
2000-11-28 |
2007-11-08 |
Seattle Genetics, Inc. |
Recombinant Anti-Cd30 Antibodies and Uses Thereof
|
|
CA2556752C
(en)
|
2004-02-23 |
2016-02-02 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
TW200539855A
(en)
|
2004-03-15 |
2005-12-16 |
Wyeth Corp |
Calicheamicin conjugates
|
|
US7750116B1
(en)
|
2006-02-18 |
2010-07-06 |
Seattle Genetics, Inc. |
Antibody drug conjugate metabolites
|
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
|
RU2448979C2
(ru)
|
2006-12-14 |
2012-04-27 |
Ридженерон Фармасьютикалз, Инк. |
Антитела человека к дельта-подобному лиганду-4 человека
|
|
WO2008122039A2
(en)
|
2007-04-02 |
2008-10-09 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Selenocysteine mediated hybrid antibody molecules
|
|
US7985557B2
(en)
|
2007-05-23 |
2011-07-26 |
Ventana Medical Systems, Inc. |
Polymeric carriers for immunohistochemistry and in situ hybridization
|
|
UA108598C2
(xx)
|
2008-04-30 |
2015-05-25 |
|
Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
|
|
ES2560807T3
(es)
|
2008-07-21 |
2016-02-22 |
Polytherics Limited |
Nuevos reactivos y procedimiento de conjugación de moléculas biológicas
|
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
|
DK2889624T3
(en)
|
2009-08-10 |
2018-12-10 |
Ucl Business Plc |
Reversible covalent bonding of functional molecules
|
|
PT2528625E
(pt)
|
2010-04-15 |
2013-10-17 |
Spirogen Sarl |
Pirrolobenzodiazepinas e conjugados das mesmas
|
|
US20130244905A1
(en)
|
2010-07-06 |
2013-09-19 |
Ed Grabczyk |
Reporter for RNA Polymerase II Termination
|
|
JP5828902B2
(ja)
|
2010-10-29 |
2015-12-09 |
イミュノジェン， インコーポレイテッド |
非拮抗性ｅｇｆｒ結合分子およびその免疫複合体
|
|
DK2714685T3
(en)
|
2011-05-27 |
2017-01-09 |
Ambrx Inc |
FORMATIONS CONTAINING, METHODS INVOLVING, AND USES OF NON-NATURAL AMINO ACID BOUND dolastatin
|
|
US8815226B2
(en)
|
2011-06-10 |
2014-08-26 |
Mersana Therapeutics, Inc. |
Protein-polymer-drug conjugates
|
|
CA2850375C
(en)
|
2011-10-14 |
2019-07-02 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
AU2012322934B2
(en)
|
2011-10-14 |
2016-09-08 |
Medimmune Limited |
Pyrrolobenzodiazepines
|
|
JP6166728B2
(ja)
|
2011-10-14 |
2017-07-19 |
メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ |
ピロロベンゾジアゼピンの製造に有用な合成方法及び中間体
|
|
CA2850373C
(en)
|
2011-10-14 |
2019-07-16 |
Seattle Genetics, Inc. |
Pyrrolobenzodiazepines and targeted conjugates
|
|
WO2013068874A1
(en)
|
2011-11-11 |
2013-05-16 |
Pfizer Inc. |
Antibody-drug conjugates
|
|
BR112014013526A8
(pt)
|
2011-12-05 |
2017-06-13 |
Igenica Biotherapeutics Inc |
conjugados de anticorpo-fármaco e compostos, composições e métodos relacionados
|
|
HRP20180268T4
(hr)
|
2012-10-23 |
2026-03-27 |
Synaffix B.V. |
Modificirano antitijelo, konjugat antitijela i postupak za njihovu pripremu
|
|
MX367748B
(es)
|
2012-12-21 |
2019-09-04 |
Glenmark Pharmaceuticals Sa |
Formulación de anticuerpo anti her2.
|
|
EP3964237B1
(en)
|
2013-03-15 |
2026-02-18 |
Regeneron Pharmaceuticals, Inc. |
Biologically active molecules, conjugates thereof, and therapeutic uses
|
|
AU2014311361B2
(en)
|
2013-08-26 |
2018-11-29 |
Regeneron Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses
|
|
JP6510532B2
(ja)
*
|
2013-12-20 |
2019-05-08 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性ｈｅｒ２抗体及び使用方法
|
|
CA2943299A1
(en)
|
2014-04-11 |
2015-10-15 |
Medimmune, Llc |
Bispecific her2 antibodies
|
|
CA2978340C
(en)
|
2015-03-27 |
2024-05-28 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
|
MX390630B
(es)
|
2016-01-25 |
2025-03-21 |
Regeneron Pharma |
Derivados de maitansinoide, conjugados de los mismos y metodos de uso.
|
|
WO2018044540A1
(en)
|
2016-08-31 |
2018-03-08 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for detecting protein trafficking
|
|
CA3042428A1
(en)
|
2016-11-08 |
2018-05-17 |
Regeneron Pharmaceuticals, Inc. |
Steroids and protein-conjugates thereof
|
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
|
|
JP7737220B2
(ja)
*
|
2017-03-31 |
2025-09-10 |
メルス ナムローゼ フェンノートシャップ |
ＮＲＧ１融合遺伝子を有する細胞の処置における使用のためのＥｒｂＢ－２及びＥｒｂＢ３結合二重特異性抗体
|
|
US20200291130A1
(en)
*
|
2017-03-31 |
2020-09-17 |
Merus N.V. |
Antibodies for the treatment of erbb-2/erbb-3 positive tumors
|
|
JP7328990B2
(ja)
|
2018-04-30 |
2023-08-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用
|
|
CA3166619A1
(en)
|
2020-02-28 |
2021-09-02 |
Julian Andreev |
Bispecific antigen binding molecules that bind her2, and methods of use thereof
|